Postmenopausal women tired of taking pills to strengthen brittle bones will soon have another option to fight osteoporosis: a twice-yearly injection. The U.S. Food & Drug Administration last week ...

A blockbuster Amgen drug for osteoporosis now carries the FDA’s strictest warning that its use can lead to dangerously low levels of calcium in the blood. This complication, hypocalcemia, is a ...

--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...

(Reuters) - Amgen Inc, the world's largest biotechnology company, said U.S. health regulators approved its Prolia injection for a new use as a treatment to increase bone mass in men with osteoporosis ...

PROLIA (denosumab) 60mg subcutaneous injection by Amgen Amgen announced that the FDA approved a new indication for Prolia (denosumab injection) as a treatment to increase bone mass in men with ...

Dr. Keith Roach writes a medical question-and-answer column weekdays. Dear Dr. Roach: My wife’s doctor wants her to start Prolia shots for bone density, but the reviews I have been reading are ...

New 2-Year Open-Label Study Shows More Than 90 Percent of Patients Preferred Prolia Injection Every Six Months Over Weekly Oral Alendronate THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen ...

Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and in men at high risk for fracture ...

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term competition thanks to a new agreement between Amgen and Celltrion. Late last week, ...